Actinium Pharmaceuticals logo

Actinium Pharmaceuticals Share Price (NYSE: ATNM)

$1.78

0.07

(4.09%)

Live

Last updated on

Check the interactive Actinium Pharmaceuticals Stock chart to analyse performance

Actinium Pharmaceuticals stock performance

as on August 23, 2025 at 12:36 AM IST

  • Today's Low:$1.75
    Today's High:$1.78

    Day's Volatility :1.69%

  • 52 Weeks Low:$1.03
    52 Weeks High:$2.41

    52 Weeks Volatility :57.29%

Actinium Pharmaceuticals Stock Returns

PeriodActinium Pharmaceuticals IncIndex (Russel 2000)
3 Months
6.1%
0.0%
6 Months
48.72%
0.0%
1 Year
-14.71%
0.0%
3 Years
-70.56%
-7.7%

Actinium Pharmaceuticals Inc Key Stats

Check Actinium Pharmaceuticals key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$1.71
Open
$1.66
Today's High
$1.78
Today's Low
$1.73
Market Capitalization
$53.3M
Today's Volume
$109.8K
52 Week High
$2.41
52 Week Low
$1.0292
Revenue TTM
$81.0K
EBITDA
$-44.0M
Earnings Per Share (EPS)
$-1.31
Profit Margin
0.0%
Quarterly Earnings Growth YOY
0.0%
Return On Equity TTM
-130.59%

Stock Returns calculator for Actinium Pharmaceuticals Stock including INR - Dollar returns

The Actinium Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Actinium Pharmaceuticals investment value today

Current value as on today

₹91,510

Returns

₹8,490

(-8.49%)

Returns from Actinium Pharmaceuticals Stock

₹12,745 (-12.75%)

Dollar Returns*

₹4,255 (+4.25%)

Indian investors sentiment towards Actinium Pharmaceuticals Stock

240%

Period: Jul 22, 2025 to Aug 21, 2025. Change in 30 Days versus previous period

Search interest for Actinium Pharmaceuticals Stock from India on INDmoney has increased by 240% in the last 30 days, reflecting an upward trend in search activity.

Analyst Recommendation on Actinium Pharmaceuticals Stock

Rating
Trend

Buy

    91%Buy

    8%Hold

    0%Sell

Based on 12 Wall street analysts offering stock ratings for Actinium Pharmaceuticals(by analysts ranked 0 to 5 stars)

Actinium Pharmaceuticals Share Price Target

What analysts predicted

Upside of 180.9%

Target:

$5.00

Current:

$1.78

Actinium Pharmaceuticals share price target is $5.00, a slight Upside of 180.9% compared to current price of $1.78 as per analysts' prediction.

Actinium Pharmaceuticals Stock Insights

  • Price Movement

    In the last 6 months, ATNM stock has moved up by 48.7%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 81.0K → 810.0K (in $), with an average increase of 90.0% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -15.93M → -6.87M (in $), with an average increase of 131.7% per quarter
  • ATNM vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 68.3% return, outperforming this stock by 83.0%
  • ATNM vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 114.2% return, outperforming this stock by 183.7%
  • Price to Sales

    ForATNM every $1 of sales, investors are willing to pay $580.0, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $24.6 for every $1 of sales.

Actinium Pharmaceuticals Technicals Summary

Sell

Neutral

Buy

Actinium Pharmaceuticals is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Actinium Pharmaceuticals Inc Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Actinium Pharmaceuticals Inc logo
-6.95%
48.72%
-14.71%
-70.56%
-80.36%
Regeneron Pharmaceuticals, Inc. logo
4.5%
-14.59%
-49.64%
-0.73%
0.56%
Beone Medicines Ltd logo
6.48%
22.93%
60.47%
81.44%
32.24%
Vertex Pharmaceuticals Incorporated logo
-16.69%
-17.94%
-17.2%
38.81%
48.58%
Alnylam Pharmaceuticals, Inc. logo
43.34%
86.27%
68.31%
115.22%
254.29%

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company advances two clinical stage product candidates, Actimab-A, to treat patients with myeloid malignancies including acute myeloid leukemia and myelodysplastic syndromes; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T for various blood cancer indications and gene therapies for non-malignant hematologic disorders such as sickle cell disease. It also develops ATNM-400, a preclinical non-prostate specific-membrane antigen targeting radiotherapy utilizing the Actinium-225 radioisotope for patients with prostate cancer. In addition, the company's Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). Further, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies, and its research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company is based in New York, New York.
Organization
Actinium Pharmaceuticals
Employees
27
CEO
Mr. Sandesh C. Seth M.B.A., M.S.
Industry
Health Technology

Key Management of Actinium Pharmaceuticals Inc

NameTitle
Mr. Sandesh C. Seth M.B.A., M.S.
Chairman & CEO
Mr. Steven O'Loughlin BS
CFO & Corporate Secretary
Dr. Paul Diamond Esq., Ph.D.
Vice President of Patent & Legal Counsel
Dr. Avinash Desai M.D.
Chief Medical Officer
Ms. Jenny Hsieh
Chief Strategy Officer
Ms. Caroline Yarbrough
Chief Commercial Officer
Ms. Lynn M. Bodarky M.B.A.
Chief Business Officer
Mr. J. C. Simeon
Executive Director of Quality Assurance
Dr. Madhuri Vusirikala M.D.
Vice President of Clinical Development BMT & Cellular Therapy

Important FAQs about investing in ATNM Stock from India :

What is Actinium Pharmaceuticals share price today?

Actinium Pharmaceuticals share price today is $1.78 as on . Actinium Pharmaceuticals share today touched a day high of $1.78 and a low of $1.75.

What is the 52 week high and 52 week low for Actinium Pharmaceuticals share?

Actinium Pharmaceuticals share touched a 52 week high of $2.41 and a 52 week low of $1.03. Actinium Pharmaceuticals stock price today i.e. is trending at $1.78, lower by 26.14% versus the 52 week high.

How to invest in Actinium Pharmaceuticals Stock (ATNM) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Actinium Pharmaceuticals on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Actinium Pharmaceuticals Shares that will get you 0.8427 shares as per Actinium Pharmaceuticals share price of $1.78 per share as on August 23, 2025 at 12:36 AM IST.

What is the minimum amount required to buy Actinium Pharmaceuticals Stock (ATNM) from India?

Indian investors can start investing in Actinium Pharmaceuticals (ATNM) shares with as little as ₹87.499 or $1 (as of August 22, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹874.99 in Actinium Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on August 22, 2025). Based on Actinium Pharmaceuticals share’s latest price of $1.78 as on August 23, 2025 at 12:36 AM IST, you will get 5.6180 shares of Actinium Pharmaceuticals. Learn more about fractional shares .

What are the returns that Actinium Pharmaceuticals has given to Indian investors in the last 5 years?

Actinium Pharmaceuticals stock has given -80.36% share price returns and 17.97% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your US Stock Investments?